The UK and US have finalized a significant bilateral deal that will preserve zero levies on British pharmaceutical exports being sold in the US market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has agreed to raise spending on medicines through the National Health Service (NHS). This pledge guarantees that duties on these crucial products will be held at zero for a timeframe of three years.
This deal comes after recent warnings to significantly raise duties on branded drug imports, with increases discussed up to double the cost.
"This agreement between the Britain strengthens the worldwide climate for new treatments and brings long-overdue balance to U.S.–U.K. medicine commerce," an announcement declared.
Trade Importance
Drugs represent one of the Britain's largest export categories to the US, which is easily the largest buyer for leading British pharmaceutical firms.
Statistics reveal that in the year leading up to the third quarter, the UK shipped pharmaceutical products valued at over eleven billion pounds to the US. This amount made up 17.4% of all goods exports in that period.
"This guarantee secures work, increases capital expenditure and facilitates the UK to establish itself as a worldwide center for life sciences," the Business and Trade Secretary commented.
Detailed NHS Changes
The pact involves several key pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the price threshold at which it deems new treatments to be too expensive by 25%.
- Increased NHS Spending: There is a target to increase total health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Payback Limit: The percentage pharmaceutical firms must refund to the NHS to control costs will be capped at fifteen percent. In the past, refunds topped 20%.
Recent Tensions
This agreement follows a long-running dispute between the drug companies and the ministers over spending levels and NHS adoption.
The disagreement were intensified by claims that American customers were paying several times more for the identical medicines than people in the Britain and the EU.
Recently, several major drug company projects in the UK have been delayed or scrapped, while substantial expansions have been announced toward American operations.
One official acknowledged that the NHS had to spend more on treatments, noting that its spending on drugs had declined as a percentage of its total funding over the past decade.
